Literature DB >> 15889532

Oligonucleotides and polyribonucleotides: a review of antiviral activity.

Michael Markosian1, Robyn M Hyde.   

Abstract

Current antiviral therapies are insufficient for treating emerging, re-emerging and established viral diseases. In an effort to find new therapeutics, oligo- and polyribonucleotides are being studied for their antiviral capabilities. Studies have shown that uniquely modified single- and double-stranded nucleic acid constructs are effective in inhibiting viral proliferation by various mechanisms. This review gives a brief history and highlights the development of oligo- and polyribonucleotides as antiviral agents primarily in the fields of interferon induction, mRNA complementation and reverse transcriptase inhibition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889532     DOI: 10.1177/095632020501600202

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  4 in total

1.  Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.

Authors:  Raffaella Gesuete; Amy E B Packard; Keri B Vartanian; Valerie K Conrad; Susan L Stevens; Frances R Bahjat; Tao Yang; Mary P Stenzel-Poore
Journal:  J Neurochem       Date:  2012-11       Impact factor: 5.372

2.  Poly-IC preconditioning protects against cerebral and renal ischemia-reperfusion injury.

Authors:  Amy E B Packard; Jason C Hedges; Frances R Bahjat; Susan L Stevens; Michael J Conlin; Andres M Salazar; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-16       Impact factor: 6.200

Review 3.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

Review 4.  Function and mechanism of toll-like receptors in cerebral ischemic tolerance: from preconditioning to treatment.

Authors:  Peng-Fei Wang; Xiao-Yi Xiong; Jing Chen; Yan-Chun Wang; Wei Duan; Qing-Wu Yang
Journal:  J Neuroinflammation       Date:  2015-04-28       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.